Bibliography
- Perrault I, Rozet JM, Calvas P, et al. Retinal-specific guanylate cyclase gene mutations in Leber’s congenital amaurosis. Nat Genet 1996;14(4):461-4
- Den Hollander AI, Roepman R, Koenekoop RK, Cremers FPM. Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog Retin Eye Res 2008;27(4):391-419
- Mihelec M, Pearson RA, Robbie SJ, et al. Long-term preservation of cones and improvement in visual function following gene therapy in a mouse model of leber congenital amaurosis caused by guanylate cyclase-1 deficiency. Hum Gene Ther 2011;22(10):1179-90
- European Medicines Agency. Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 8 containing the human GUCY2D gene for the treatment of Leber’s congenital amaurosis. 2014
- Van Til NP, Sarwari R, Visser TP, et al. Recombination-activating gene 1 (Rag1)–deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome. J Allergy Clin Immunol 2014;133(4):1116-23
- Pike-Overzet K, Rodijk M, Ng YY, et al. Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer. Leukemia 2011;25(9):1471-83
- European Medicines Agency. Public summary of opinion on orphan designation: Autologous CD34+ cells transduced with a lentiviral vector containing the human RAG1 gene for the treatment of recombination - activating gene 1 deficient severe combined immunodeficiency. 2014
- Krajewski KM, Lewis RA, Fuerst DR, et al. Neurological dysfunction and axonal degeneration in Charcot–Marie–Tooth disease type 1A. Brain 2000;123(7):1516-27
- Pareyson D, Marchesi C. Natural history and treatment of peripheral inherited neuropathies. In: Espinós C, Felipo V, Palau F, editors. Inherited neuromuscular diseases. Springer, Netherlands; 2009. p. 207-24
- European Medicines Agency. Public summary of opinion on orphan designation:Fixed-dose combination of (R-S) baclofen, naltrexone hydrochloride and D-sorbitol for the treatment of Charcot-Marie-Tooth disease type 1A. 2014
- Attarian S, Magy L, Franques J, et al. Comparative analysis of clinical and electrophysiological data collected on patients with Charcot-Marie-Tooth disease type 1A enrolled in the Ascorbic Acid and the PXT3003 clinical trials. 2013
- Dobson NR, Patel RM, Smith PB, et al. Trends in caffeine use and association between clinical outcomes and timing of therapy in very low birth weight infants. J Pediatr 2014;164(5):992-998.e993
- Clark H, Reid K. The potential of recombinant surfactant protein D therapy to reduce inflammation in neonatal chronic lung disease, cystic fibrosis, and emphysema. Arch Dis Child 2003;88(11):981-4
- Sato A, Whitsett JA, Scheule RK, Ikegami M. Surfactant protein-d inhibits lung inflammation caused by ventilation in premature newborn lambs. Am J Respir Crit Care Med 2010;181(10):1098-105
- European Medicines Agency. Public summary of opinion on orphan designation: caffeine citrate for the prevention of bronchopulmonary dysplasia. 2014
- European Medicines Agency. Public summary of opinion on orphan designation: recombinant surfactant protein D for the prevention of bronchopulmonary dysplasia. 2014.